Posted by Michael Wonder on 30 Jul 2024
Syndax announces PDUFA action date extension for revumenib NDA for relapsed or refractory KMT2Ar acute leukaemia
29 July 2024 - New PDUFA action date of 26 December 2024 allows FDA additional time to complete their review.
Syndax Pharmaceuticals today announced that the US FDA has extended the PDUFA action date for the new drug application for revumenib for the treatment of adults and paediatric patients with relapsed or refractory KMT2Ar acute leukaemia.
